- Home
- TURN vs DXR Comparison
TURN vs DXR Comparison
Compare TURN & DXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TURN
- DXR
- Stock Information
- Founded
- TURN 1981
- DXR 1970
- Country
- TURN United States
- DXR United States
- Employees
- TURN N/A
- DXR N/A
- Industry
- TURN Finance/Investors Services
- DXR Medical/Dental Instruments
- Sector
- TURN Finance
- DXR Health Care
- Exchange
- TURN Nasdaq
- DXR Nasdaq
- Market Cap
- TURN 39.9M
- DXR 36.4M
- IPO Year
- TURN N/A
- DXR N/A
- Fundamental
- Price
- TURN $3.93
- DXR $9.25
- Analyst Decision
- TURN
- DXR Strong Buy
- Analyst Count
- TURN 0
- DXR 1
- Target Price
- TURN N/A
- DXR $25.00
- AVG Volume (30 Days)
- TURN 20.3K
- DXR 2.8K
- Earning Date
- TURN 06-17-2025
- DXR 01-01-0001
- Dividend Yield
- TURN N/A
- DXR N/A
- EPS Growth
- TURN N/A
- DXR 86.16
- EPS
- TURN N/A
- DXR 0.11
- Revenue
- TURN $194,813.00
- DXR $119,714.00
- Revenue This Year
- TURN N/A
- DXR N/A
- Revenue Next Year
- TURN N/A
- DXR N/A
- P/E Ratio
- TURN N/A
- DXR $81.69
- Revenue Growth
- TURN 254.25
- DXR N/A
- 52 Week Low
- TURN $3.12
- DXR $6.55
- 52 Week High
- TURN $4.25
- DXR $10.00
- Technical
- Relative Strength Index (RSI)
- TURN 45.33
- DXR 73.43
- Support Level
- TURN $3.90
- DXR $8.29
- Resistance Level
- TURN $4.05
- DXR $8.13
- Average True Range (ATR)
- TURN 0.17
- DXR 0.32
- MACD
- TURN -0.02
- DXR 0.14
- Stochastic Oscillator
- TURN 24.42
- DXR 100.00
About TURN 180 Degree Capital Corp.
180 Degree Capital Corp is active in the financial services domain. It is a non-diversified closed-end management investment company whose objective is to achieve long-term capital appreciation by making venture capital investments. It focuses its investments on companies commercializing and integrating products enabled by disruptive technologies mainly in the life sciences, precision medicine, and health industries.
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.